Clinical Trial Update: Bevacizumab Plus Chemotherapy for Advanced Non Small Cell Lung Cancer Patients as 1st Line Treatment

View source ↗

Summary

This clinical trial update reports on a completed study of Bevacizumab plus chemotherapy as first-line treatment for advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Hellenic Oncology Research Group | Conditions: Non Small Cell Lung Cancer | Status: COMPLETED